Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline
NEW YORK, January 7, 2026, 19:17 EST — After-hours Amgen shares (AMGN.O) rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price target, saying it sees “upside from EPS and pipeline.” Why this matters now is simple: investors are testing whether Amgen’s next growth bets can outrun erosion in older blockbusters. The FDA on Tuesday approved Amneal’s denosumab biosimilars — near-copies of complex biologic drugs that typically enter at lower prices — as alternatives to Amgen’s Prolia and Xgeva, products with about
